Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2018 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ROCKVILLE, MD, April 02, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
March 28, 2018 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Pricing of Public Offering of Common Stock

ROCKVILLE, MD, March 28, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
March 26, 2018 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Proposed Public Offering of Common Stock

ROCKVILLE, MD, March 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
March 09, 2018 07:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present at Cowen Health Care Conference

Rockville, MD, March 09, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
February 27, 2018 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and 2017 Financial Results

ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
February 14, 2018 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter and Full Year 2017 Financial Results Conference Call

ROCKVILLE, MD, Feb. 14, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
February 06, 2018 17:30 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Two Upcoming Investor Conferences

ROCKVILLE, MD, Feb. 06, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
January 23, 2018 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis

Rockville, MD, Jan. 23, 2018 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
January 18, 2018 14:00 ET | Source: MacroGenics, Inc.

Phase 1b/2 Study of Margetuximab in Combination with Pembrolizumab Presented at 2018 ASCO Gastrointestinal Cancers Symposium

Chemotherapy-free, immunotherapeutic combination evaluated32% Overall response rate in second-line gastric cancer patientsWell tolerated in dose escalation and expansion cohorts Rockville, MD, Jan. ...
January 04, 2018 17:15 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 36th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD, Jan. 04, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...